跳至主要内容
临床试验/NCT03117010
NCT03117010招募中不适用

A Prospective Cohort for Subjects With Adult Hemophagocytic Lymphohistiocytosis Like Syndrome

Samsung Medical Center2 个研究点 分布在 2 个国家目标入组 81 人开始时间: 2017年1月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
招募中
入组人数
81
试验地点
2
主要终点
Response

研究概览

简要总结

This prospective study enrolls subjects who have clinical and laboratory manifestations related with hemophagocytic lymphohistiocytosis. The purpose of the study is to evaluate clinical and biological features of adult hemophagocytic lymphohistiocytosis. The enrolled subjects into this study will be evaluated according to the HLH (hemophagocytic lymphohistiocytosis)criteria and treated with systemic immunosuppressive therapy or chemotherapy. All subjects will be regularly monitored by physicians participating in this study.

详细描述

Study process is as follows.

  1. Informed consent for subjects fulfilling the inclusion criteria.
  2. Laboratory evaluation will be done for subjects according to the following diagnostic criteria.
  • Diagnosis will be established if one of either 1 or 2 below is fulfilled
  1. A molecular diagnosis consistent with HLH
  2. Diagnostic criteria for HLH fulfilled (5 out of 8 criteria below)
  • fever ≥ 38.5'C for ≥ 7 days
  • splenomegaly ≥ 3 finger breadth below left subcostal margin
  • cytopenias affecting ≥2 of 3 lineages in peripheral blood (Hemoglobin < 9 g/L, Platelets < 100 × 109/L, Absolute neutrophil count < 1.0 × 109/L)
  • Hypertriglyceridemia and/or hypofibrinogenemia: Fasting triglycerides ≥ 265 mg/dL, fibrinogen ≤ 1.5 g/L
  • Hemophagocytosis in bone marrow or spleen or lymph node
  • Low or absent NK-cell activity (according to local laboratory reference)
  • Ferritin ≥ 500 mcg/L
  • Soluble CD25 (sIL-2 receptor) ≥ 2,400 U/mL

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects should fulfill the following criteria
  • Subjects should have at least one of the following problems
  • Presence of hemophagocytosis in tissue or bone marrow
  • Presence of at least 3 conditions among 8 conditions of HLH diagnostic criteria
  • Age > 18 years
  • Written informed consents

排除标准

  • Subjects cannot satisfy the inclusion criteria

研究组 & 干预措施

Hemophagocytosis

Subjects should fulfill the following criteria

  1. Subjects should have at least one of the following problems

  2. Presence of hemophagocytosis in tissue or bone marrow

  3. Presence of at least 3 conditions among 8 conditions of HLH diagnostic criteria

  4. Age > 18 years

  5. Written informed consents

Subjects receive steroids and etoposide

干预措施: Steroids (Drug)

Hemophagocytosis

Subjects should fulfill the following criteria

  1. Subjects should have at least one of the following problems

  2. Presence of hemophagocytosis in tissue or bone marrow

  3. Presence of at least 3 conditions among 8 conditions of HLH diagnostic criteria

  4. Age > 18 years

  5. Written informed consents

Subjects receive steroids and etoposide

干预措施: Etoposide (Drug)

结局指标

主要结局

Response

时间窗: 28 days after the 1st treatment

Response to steroids and etoposide

次要结局

  • Progression-free survival(3 years)
  • Overall survival(3 years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验